MSF Access Campaign

24/09/2025

Scientists who discovered over 100 years ago envisioned a world where everyone could access diabetes treatment.

And yet, diabetes treatment is too often unavailable or unaffordable.

Learn more ⬇️

17/09/2025

Even with access to the best tools, technology, and treatment, managing diabetes is complicated.

What happens when people face challenges accessing the diabetes care they need due to corporate decisions, displacement, or conflict?

Hear from Lecritia, Sana, and Ghassan, whose lives were impacted when they had to manage their diabetes without access to the medical tools they needed and preferred.

Managing diabetes is complicated. Even with access to the best tools and technology, it requires constant blood sugar level monitoring and daily treatment in the form of medication or insulin.

12/09/2025

In 2024, only 16% of children in the Central African Republic had completed their full vaccination schedule, while 34% had never received any vaccine.

In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations.

Reaching more children in fragile & humanitarian settings like war zones, refugee camps, and hard-to-reach areas cut off from healthcare requires increased global investment in vaccination for children up to at least the age of 5.

Read more, below.

https://msfaccess.org/gavi-plans-next-five-year-strategy-it-must-do-more-get-vaccines-people-excluded-vaccination

05/09/2025

Today marks a critical milestone on the path towards increasing access to treatment:

✔️ Rapid-acting insulin analogues and GLP-1 agonists have been added to the Model List of Essential Medicines (EML).

But why is EML important?

Inclusion in the WHO Essential Medicines List signals that a medicine is vital for public health and should be made affordable and accessible; that countries should include it in national policies; and that corporations should register it in-country.

However, today’s prices are unacceptably high.

According to a recent MSF study:
Rapid-acting insulin analogues are priced up to 75 times more than what they can be profitably produced for, and GLP-1 agonists up to 400 times more than what they can be profitably produced for!

“In our experience of providing diabetes care in low-resource settings and humanitarian emergencies, rapid-acting insulins and GLP-1s are unaffordable and often unavailable.”

https://msfaccess.org/msf-responds-inclusion-rapid-acting-insulin-analogues-and-glp-1s-who-essential-medicines-list

13/08/2025

The public health goals in low- and middle-income countries (LMICs) cannot be achieved without effective, accessible, and affordable tools which are fit for the environment of these countries.

Join us for a hybrid event at Tokyo International Conference on African Development where we will discuss challenges & solutions for accessing diagnostics in Africa, feature MSF field innovations and explore collaborations with Japan.

Date: 21 August 2025 (Thursday)
Time: 18:00-19:30 (Japan Time)
Venue: PACIFICO Yokohama & Zoom Webinar
Language: English
Registration: Pre-registration is required for virtual attendance. Register at https://www.msf.or.jp/event/detail/20250821.html

14/07/2025

MSF welcomes World Health Organization (WHO)’s new guidelines for lenacapavir, a game-changing prevention drug. But we’re deeply concerned about restricted access due to Gilead’s licensing limitation.

“Lenacapavir is the kind of innovation that can be transformative, but only if it is ultimately accessible to communities in low- and middle-income countries that most need it,” says Antonio Flores, Senior HIV/TB Advisor for MSF Southern Africa Medical Unit (SAMU).

New drug Lenacapavir is an HIV prevention tool which offers greater choice and longer protection, and high effectiveness for people wishing to protect themselves from acquiring HIV through a twice-yearly injection.

10/07/2025

People with in the EU/EEA region continue to face delayed or outdated access to treatment due to the unavailability, high price and fragmented supply of TB medicines. Read our policy brief that outlines barriers to accessing TB medicines, highlights regulatory and procurement pathways and flexibilities enshrined in EU legislation, and provides urgent recommendations for the region.

MSF policy brief outlining barriers to accessing TB medicines in the EU/EEA region and recommendations to overcome them.

13/06/2025

Insulin pens must be affordable and available for all people with who need them. Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes.

So, while we welcome the news that Novo Nordisk will supply South Africa with analogue insulin pens, the price is too high.

All insulin pens should be $1 per pen so that more people with diabetes can access their preferred insulin delivery device.

https://msfaccess.org/msf-welcomes-novo-nordisks-commitment-supply-south-africa-analogue-insulin-pens-price-must-come

12/06/2025

We welcome the news that Novo Nordisk will supply South Africa with analogue insulin pens, but the price Novo Nordisk is charging per pen is too high at $3.95 per pen.

We’re calling for all insulin pens to be available at $1 per pen, so that everyone can access the highest standard of diabetes treatment, especially as their cost of production is estimated to be as low as $0.94 per pen, including a profit.

Novo Nordisk starts supply of analogue insulin pens to South Africa but price remains high still. All insulin pens must be available at $1 per pen.

28/05/2025

MSF took the floor at World Health Organization (WHO) World Health Assembly. Our statements included calls for Member States to implement the new Pandemic Agreement, and to prioritise universal access to care for diabetes, mental health conditions, and cervical cancer.

Read more:

MSF statements at the 78th session of the World Health Assembly (WHA) 19–27 May 2025.

15/05/2025

⚠️South Africa: Lifesaving scientific research on prevention, testing, treatment and care for people living with and is under serious threat due to funding suspensions and grant terminations U.S. government.

TAG and MSF urge donors to act now to protect ongoing research and ensure continuity of care for people with HIV and TB

28/04/2025

Every child should be able to be protected from vaccine-preventable diseases. However, various logistical barriers mean that vaccines often don’t reach everyone who needs them, especially children living in conflict zones, refugee camps, and hard-to-reach areas.

During hashtag , we share what needs to happen to make sure vaccines reach children everywhere, including how an ambitiously funded Gavi, the Vaccine Alliance can help make this happen.

For the full story, read: “A shot at life: how to reach more children in humanitarian settings with lifesaving vaccination,” by MSF’s Victorine de Milliano and Pamela Onango in Health Policy Watch: https://healthpolicy-watch.news/a-shot-at-life-how-to.../